Roche agrees to acquire 89bio for about $3.5bn
( September 17, 2025, 15:30 GMT | Official Statement) -- MLex Summary: Basel, Switzerland-based pharmaceutical company Roche has agreed to acquire San Francisco-based 89bio, a clinical-stage biopharmaceutical company developing therapies for the treatment of liver and cardiometabolic diseases, for about $3.5 billion. Roche is traded on the SIX Swiss Exchange and 89bio is traded on the Nasdaq. The deal is expected to close in the fourth quarter of 2025. The deal would give Roche 89bio’s pegozafermin, an FGF21 analog currently in late-stage development for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in moderate and severe fibrotic and cirrhotic patients. MASH is one of the most prevalent comorbidities of obesity. The transaction is expected to close in the fourth quarter of 2025.Statement follows in full. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.